ATAI Life Sciences (NASDAQ:ATAI) is a biotechnology company focused on pioneering the development of psychedelic and non-psychedelic compounds for various mental health conditions. Dedicated to transforming mental healthcare, ATAI explores the therapeutic potential of emerging substances to address unmet needs. The company's diverse portfolio includes projects aimed at developing treatments for conditions like depression, anxiety, and addiction. ATAI emphasizes a science-led approach, leveraging innovative technologies and research to create solutions that could significantly improve patient outcomes in the mental health space.